Nova Pulse IVF Clinics, the prominent chain of IVF Clinics strengthened its ongoing efforts to provide medical treatment of international standards and world class technology to improve the efficacy of IVF treatment in India. Nova Pulse IVF Clinics in association with IVI, the leading medical institute in the field of assisted reproduction, announced the launch of the revolutionary ‘Endometrial Receptivity Assay’ (ERA) for the very first time in India. This association is an attempt to help women who face unexplained IVF failures due to poor uterine or endometrial receptivity.
Endometrial Receptivity Assay is an innovative test that has been solely developed and designed at IVI Medical Institute. Backed by the celebrated lineage of IVI institute and supported by cutting edge technologies, the Endometrial Receptivity Test promises to be the next big innovation in the Medical industry. In India, Nova Pulse IVF Clinics have been the very first medical center to be allowed by IVI to use their technology and make the test available to the public.
The breakthrough medical test, before being publicly available, has gone through an extended period of randomised, restricted clinical trials at multiple centers in Spain. The test involved 150 patients with Implantation Failures. Initial test results showed that 25 percent of them were non-receptive, and correlate with more than 95 percent to non-pregnancy. The stringent protocol of Nova Pulse IVF Clinics ensured that the Endometrial Receptivity Genomic Diagnostic Test was carefully developed by taking into account the molecular signature (RNAm) of 238 genes selected for endometrial receptivity.